Mounjaro

Eli Lilly And Co (NYSE:LLY) is scheduled to report its quarterly results on Thursday. The company is likely to report its first-quarter results in line with peers, with some tariff and policy-related commentary during the earnings call, according to Goldman Sachs. The Eli Lilly Analyst: Analyst...

Weight loss drugs have taken the world by storm and saw strong demand for the companies selling them. A new study shows that despite the increase usage of weight loss drugs, obesity is still on the rise and could hit staggering numbers in the next 25 years. What Happened: The public support of...

The world’s richest man Elon Musk earlier this week admitted to using the weight loss drug Mounjaro. What Happened: Musk on Christmas posted a picture of himself donning the Santa Claus costume with the caption “Ozempic Santa.” Ozempic Santa pic.twitter.com/7YECSNpWoz —...

An endorsement of a weight-loss drug by world's richest man Elon Musk could prove beneficial in the battle between two health care companies seeing revenue growth and soaring stock prices as interest in weight-loss drugs grows. What Happened: A post from Musk on Christmas shared his latest take on...

Eli Lilly and Co (NYSE:LLY) is making headlines with its $15 billion share buyback plan and a 15% dividend boost. Yet, as the Indianapolis-based pharma giant enjoys the success of blockbuster drugs like Mounjaro and Zepbound, its stock is sending mixed technical signals ahead of its next move. Eli...

Eli Lilly and Co. (NYSE:LLY) has seen better days. The stock is up 26.04% for the last year but has struggled recently, falling 17.57% over the last month. Chart created using Benzinga Pro Lilly stock is well below its summer highs and is trading at $746.94 at the time of writing. The once red-hot...

Eli Lilly & Co. (NYSE:LLY) shares have nosedived 12.5% month-to-date through Nov. 19, putting the stock on track for its worst monthly performance since February 2009, when it tumbled 20.2%. The pharmaceutical giant, which ranks 11th by market capitalization in the S&P 500 and holds the...

Eli Lilly And Co (NYSE:LLY) experienced a 1.37% increase in pre-market trading on Wednesday, as per Benzinga Pro. This uptick occurs as the company gears up to announce its third-quarter earnings. Wall Street analysts are forecasting earnings per share of $1.45 and revenues of $12.1 billion. What...

Editor’s note: This story has been updated to clarify that Eli Lilly is set to report earnings premarket Wednesday. Eli Lilly and Co (NYSE:LLY) will be reporting its third-quarter earnings on Wednesday. Wall Street expects $1.45 in EPS and $12.1 billion in revenues when the company reports...

In a groundbreaking move, Eli Lilly (NYSE:LLY) is set to test its weight-loss medications on individuals who are not overweight but are at risk of gaining weight. What Happened: Dave Ricks, CEO of Eli Lilly, announced that the company is considering lowering the BMI threshold for its anti-obesity...

Eli Lilly And Co (NYSE:LLY) is one of several companies benefitting from demand for weight loss drugs. The company is also seeing competition in the market including knockoff drugs that it said could be unsafe. What Happened: A recent report says Eli Lilly is seeking medical records of people who...

In a bid to meet escalating demand for its obesity drugs, pharmaceutical behemoth, Eli Lilly & Co. (NYSE:LLY) has funneled $800 million into its Irish operations to ramp up the production of its blockbuster drugs, Mounjaro and Zepbound. What Happened: The investment is aimed at ensuring a...

Criminals are distributing fake versions of the weight-loss drug Ozempic by forging the drug batch numbers pharmaceutical companies use to authenticate drugs and track them in a specified country. They obtain batch numbers illicitly through a liaison who works at a drugmaker factory or by buying...

Eli Lilly And Co (NYSE:LLY) reported on Thursday second-quarter revenue of $11.3 billion, up 36% year-over-year, easily surpassing the consensus of $9.95 billion. Mounjaro sales tripled to $3.09 billion from $979.7 million a year ago. Zepbound sales reached $1.24 billion, up from $...

Eli Lilly and Co. (NYSE:LLY) has come out on top in a weight loss drug competition in a recent study. The study found that patients on Lilly’s Mounjaro lost more weight than those on Novo Nordisk’s (NYSE:NVO) Ozempic. What Happened: The study, published on the JAMA Internal Medicine...